Feasibilty study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function

Clinical and Translational Oncology

Volumn 8, Issue 10, 2006, Pages 755-757

  Carles, Joan ^a   Suárez, Cristina ^a   Mesía, Carlos ^a   Nogué, Miquel ^b   Font, Albert ^c   Doménech, Montserrat ^d   Suárez, Marta ^a   Tusquets, Ignasi ^a   Gallen M ^a   Albanell, Joan ^a   Fabregat, Xavier ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL GENERAL DE VIC   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Althaia   (Spain)

Author keywords

Bladder cancer; Cisplatin; Gemcitabine; Unfit patients

Indexed keywords

CISPLATIN; CREATININE; DEXAMETHASONE; GEMCITABINE; GRANISETRON; PLATINUM; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DETERIORATION; DRUG DELIVERY SYSTEM; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; RISK ASSESSMENT; THROMBOCYTOPENIA; UROGENITAL TRACT CANCER; VOMITING; BLADDER TUMOR; BLOOD; COMPARATIVE STUDY; KARNOFSKY PERFORMANCE STATUS; METASTASIS; MIDDLE AGED; TIME; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CREATININE; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 36949026789     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0123-8     Document Type: Article

References (19)

1. Cancer Incidence in Five Continents. volume VII, Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. IARC Scientific Publications, núm 143, Lyon 1977.
2. Whitmore WF Jr. Bladder cancer: Defining the clinical problem. Urology. 1984;23:5-8.
3. Yagoda A, Watson RD, González-Vitale JC, et al. Cis-dichlorodiamineplatinum(II) in advanced bladder cancer. Cancer Treat Rep. 1976;60:917-23.
4. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-5.
5. Loehrer Sr PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992;10:1066-73.
6. Mead GM, Russell M, Clark P, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV0 in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. Br J Cancer. 1998;78:1067-75.
7. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;17:3068-77.
8. Von Hoff DD, Schilsky R, Reichter CB, et al. Toxic effects of cisdihlorodiamineplatinum (II) in man. Cancer Treat Rep. 1979;63:1527-31.
9. Bellmunt J, Ribas A, Eres N, et al. Carcoplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966-72.
10. Carteni G, Dogliotti L, Crucitta E, et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol. 2003;22:384 (abstr 1543).
11. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer. 1996;77:344-51.
12. Hussain SA, Stocken D, Riley P, et al. A phase I/II outpatient study of gemcitabine and fractioned cisplatin in advanced relapsed and metastatic bladder cancer in a 21-day schedule. Proc Am Soc Clin Oncol 2003;24 (abstract 1570).
13. Colomer R, Llombart-Coussac A, Lluch A, et al. Biweeklu paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predicitive value of HER-2 extracelular domain. Ann Oncol. 2004;15:201-6.
14. López-Vivanco G. Biweekly administration scheme with gemcitabine and cisplatin in advanced and metastatic non-small cell lung cancer. Curr. Oncol Rep. 2004;6Suppl 1:S5-7.
15. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004;22:393-7.
16. National Cancer Institute. Common Toxicity Criteria Manual. Bethesda Md. National Cancer Institute, 1999.
17. Therase P, Arbuch SG, Eisenhauer EA, et al. New guidelines to valorate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National cancer Institute of the United states and National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
18. Bellmunt J, de Witt R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003;47:195-206.
19. Nogué-Aligué M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy. Cancer. 2003;97:2180-6.